Cancer Therapy

New data released on Xcytrin's mechanism to enhance effects of radiation and chemotherapy

Published in Cancer Weekly, May 28th, 2002

Pharmacyclics, Inc., (PCYC) announced that four separate presentations at the 49th annual meeting of the Radiation Research Society (RRS) provide a more complete picture of the novel intracellular activity and mechanism of action of the company's lead product, Xcytrin (motexafin gadolinium) Injection.

"These presentations provide further evidence of the novel mechanism of action of Xcytrin to enhance the effects of radiation and chemotherapy for the potential treatment of cancer and other diseases, which is currently being tested in clinical trials," said Richard A. Miller, MD, Pharmacyclics' president and chief executive officer. "Xcytrin is the first of an entirely...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-05-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry